FucoID-based tumor antigen-specific T cell surface engineering is a novel and significant technology with multiple advantages. As a professional cell surface engineering services provider, Creative Biolabs is capable of providing high-quality FucoID-based tumor antigen-specific T cell surface engineering services.
In the past decade, the development of immune checkpoint inhibitors and adoptive cell transfer (ACT)-based therapies has revolutionized cancer treatment. The success, however, is limited to a relatively small subset of patients and cancer types. Successful anti-tumor immune responses following checkpoint blockade immunotherapy are believed to require re-activation and clonal expansion of tumor-specific antigen (TSA)-reactive T cells. The unpredictability of a patient's response to immunotherapy is partially attributed to the heterogeneity of the tumor immune microenvironment and phenotypic profiles of tumor-infiltrating lymphocytes (TILs) within individual tumors. To accelerate the pace of cancer immunotherapy, a computation-free method that enables quick TSA-reactive T cell discovery and easy adaptability would be a welcome advance.
FucoID is an identification method for antigen-specific T cells. The principle of this strategy is based on the fucosyl-biotinylation interaction. FucoID has simple procedures and a quick turnover cycle, by which isolation of endogenous TSA-reactive T cells from tumor digests will not need previous knowledge of the TSA identities. Tumor-lysate primed dendritic cells (DCs) are equipped with an especial enzyme and play roles in presenting TSAs. The enzyme equipped by these DCs is capable of inducing proximity-based transfer of fucosylated biotin (Fuc-Bio) tags to the surface of T cells that interact with the DCs.
Fig.1 Schematic representation of FucoID for the labeling of cell-cell interactions.
FucoID is a novel strategy for the characterization and manipulation of the entire repertoire of endogenous, TSA-reactive TILs. Especially, FucoID is appropriate for many murine tumor models. In addition, FucoID is a glycosyltransferase-mediated tagging approach, thus it does not rely on genetic manipulations. This feature makes it easily applicable to probe primary cell interactions. In summary, FucoID has a high potential to be translated to a clinical setting for the detection and isolation of TSA-reactive TILs from human patients.
FucoID-based tumor antigen-specific T cell surface engineering is a novel and significant technology with multiple advantages. With rich experience and strong foundations, Creative Biolabs is capable of providing high-quality FucoID-based tumor antigen-specific T cell surface engineering services to global customers. Besides FucoID, Creative Biolabs also offers many other cell surface engineering services including but not limited to:
With a comprehensive technology platform and high-quality cell surface engineering services with assurance, Creative Biolabs aspires to meet every customer's requirement. If you are interested in FucoID-based tumor antigen-specific T cell surface engineering or any other technology in our platform, please feel free to contact us for more information.
All services are only provided for research purposes and Not for clinical use.